Article informationBackground: Patients with acute leukemia [AL] may express aberrant antigens that are normally restricted to a different lineage. We evaluated the frequency of aberrancy in AL patients.Aim of the work: Evaluation and analysis of the incidence of aberrant phenotypes in mononuclear cells in AL patients and their relation to hematological parameters.
Patients and Methods: This observational descriptive study was conducted on 150 newly diagnosed cases of AL over the period from August 2017 to March 2021. Flow cytometry was performed by Becton Dickinson [BD] FACS Calibur/BD FACS Canto flow cytometers using monoclonal antibodies against cell markers. Results: The overall frequency of aberrancy was 38.7% [58/150] in all AL patients. Aberrant antigenic expression was more frequent in acute lymphoblastic leukemia [ALL] than acute myeloid leukemia [AML], T-ALL with aberrant expression was 66.6% of all T-ALL patients, while B-ALL with aberrant expression was 45.8% of all B-ALL patients, and AML with aberrant expression was 31.1% of all AML patients. Conclusion: Aberrant phenotypes were found with considerable frequency in AL patients, and the implication of aberrant markers can help in disease monitoring, detecting measurable residual disease, and determining risk stratification and treatment intensity.
Article informationBackground: Type 2 diabetes [T2D] is characterized as a complicated and varied group of metabolic conditions. The disorder's defining feature is increased blood sugar level brought on by a malfunction in insulin action and/or secretion.
Aim of the Work:To evaluate Platelet indices as predictive biomarkers for diabetic nephropathy in diabetes type 2.
Background: Diffuse large B-cell lymphoma (DLBCL) has been the most common kind of non-Hodgkin lymphoma (NHL), representing for roughly 24% of new instances per year. The HMG box 1 protein is a nuclear DNAbinding protein that was identified more than thirty years ago. It binds to DNA and functions as a cofactor in the transcription of genes. Overexpression of HMGB1 was being discovered in many cancers, including breast cancer, gastric cancer, and non-Hodgkin lymphoma. Aim of the study: to see how high mobility group box 1 protein levels are affected by DLBCL and how chemotherapy affects HMGB1 levels in DLBCL patients. Patients and Methods: This study was conducted out in oncology department of Al-Hussein University hospital. Two groups of patients were formed. Group (A): composed of 35 patients with DLBCL for whom pre-treatment and post-treatment level of HMGB1 protein were measured. Group (B): composed of 35 normal subjects act as a control group. All procedures followed Al-Azhar University Ethical Committee regulations. Results: there is statistically significant improvement after chemotherapy as t value equaled (8.632) with P-value (0.000). Also, when comparing pre-value with normal, paired t test equaled (10.16) with P-value (0.000). Using ROC curve, it was stated that area under the curve equaled 1 with standard error 0 and P=0.017.
Conclusion:The HMG box 1 protein is a significant indicator in patients with DLBCL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.